Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

Changes in laboratory value improvement and mortality rates over the course of the pandemic: an international retrospective cohort study of hospitalised patients infected with SARS-CoV-2

Producción científica: Articlerevisión exhaustiva

6 Citas (Scopus)

Resumen

Objective To assess changes in international mortality rates and laboratory recovery rates during hospitalisation for patients hospitalised with SARS-CoV-2 between the first wave (1 March to 30 June 2020) and the second wave (1 July 2020 to 31 January 2021) of the COVID-19 pandemic. Design, setting and participants This is a retrospective cohort study of 83 178 hospitalised patients admitted between 7 days before or 14 days after PCR-confirmed SARS-CoV-2 infection within the Consortium for Clinical Characterization of COVID-19 by Electronic Health Record, an international multihealthcare system collaborative of 288 hospitals in the USA and Europe. The laboratory recovery rates and mortality rates over time were compared between the two waves of the pandemic. Primary and secondary outcome measures The primary outcome was all-cause mortality rate within 28 days after hospitalisation stratified by predicted low, medium and high mortality risk at baseline. The secondary outcome was the average rate of change in laboratory values during the first week of hospitalisation. Results Baseline Charlson Comorbidity Index and laboratory values at admission were not significantly different between the first and second waves. The improvement in laboratory values over time was faster in the second wave compared with the first. The average C reactive protein rate of change was -4.72 mg/dL vs -4.14 mg/dL per day (p=0.05). The mortality rates within each risk category significantly decreased over time, with the most substantial decrease in the high-risk group (42.3% in March-April 2020 vs 30.8% in November 2020 to January 2021, p<0.001) and a moderate decrease in the intermediate-risk group (21.5% in March-April 2020 vs 14.3% in November 2020 to January 2021, p<0.001). Conclusions Admission profiles of patients hospitalised with SARS-CoV-2 infection did not differ greatly between the first and second waves of the pandemic, but there were notable differences in laboratory improvement rates during hospitalisation. Mortality risks among patients with similar risk profiles decreased over the course of the pandemic. The improvement in laboratory values and mortality risk was consistent across multiple countries.

Idioma originalEnglish
Número de artículoe057725
PublicaciónBMJ Open
Volumen12
N.º6
DOI
EstadoPublished - jun 1 2022

Nota bibliográfica

Publisher Copyright:
© 2022 BMJ Publishing Group. All rights reserved.

Financiación

GMW is supported by NIH/NCATS UL1TR002541, NIH/NCATS UL1TR000005, NIH/NLM R01LM013345, and NIH/NHGRI 3U01HG008685-05S2. BWQT is supported by the National Medical Research Council Research Training Fellowship (MOH-000195-00). FJSV is supported by NIH/NCATS UL1TR001881. DAH is supported by NIH/NCATS UL1TR002240. KBW is supported by NIH/NHLBI R01 HL151643-01. SNM is supported by NIH/NCATS 5UL1TR001857-05 and NIH/NHGRI 5R01HG009174-04. NG is supported by NIH/NLM T15 LM007092. GSO is supported by NIH P30ES017885 and U24CA210967. ZX is supported by NIH/NINDS R01NS098023. SV is supported by NIH/NLM R01LM012095 and NIH/NCATS UL1TR001857. LPP is supported by NIH/NCATS CTSA Award #UL1TR002366. DLM is supported by NIH/NCATS CTSA Award #UL1-TR001878. RK is supported by NIH/NCATS CTSA award#UL1TR001998. NG-B is supported by the Carlos III Health Institute PI18/00981. AMS is supported by NIH/NHLBI K23HL148394 and L40HL148910 and NIH/NCATS UL1TR001420.

FinanciadoresNúmero del financiador
Instituto de Salud Carlos IIIUL1TR001420, K23HL148394, L40HL148910, PI18/00981
Eunice Kennedy Shriver National Institute of Child Health and Human DevelopmentT32HD040128
National Human Genome Research Institute3U01HG008685-05S2
National Medical Research Council SingaporeUL1TR001881, UL1TR002240, MOH-000195-00
Institute of Neurological Disorders and Stroke National Advisory Neurological Disorders and Stroke CouncilR01NS124882, R01LM012095, 1TR001998, R01NS098023, 1-TR001878, 1TR002366
National Institutes of Health (NIH)L40HL148910
National Heart, Lung, and Blood Institute (NHLBI)U24CA210967, K23HL148394, 5R01HG009174-04, T15 LM007092, R01 HL151643-01, UL1TR001857
U.S. National Library of MedicineR01LM013337, R01LM013345
National Institutes of Health/National Institute of Environmental Health SciencesP30ES017885
National Center for Advancing Translational Sciences (NCATS)UL1TR001420, UL1TR002541, UL1TR000005

    ODS de las Naciones Unidas

    Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

    1. Good health and well being
      Good health and well being

    ASJC Scopus subject areas

    • General Medicine

    Huella

    Profundice en los temas de investigación de 'Changes in laboratory value improvement and mortality rates over the course of the pandemic: an international retrospective cohort study of hospitalised patients infected with SARS-CoV-2'. En conjunto forman una huella única.

    Citar esto